Tirzepatide is a novel medication developed for the treatment of type 2 diabetes and obesity. It belongs to a new class of drugs called dual GLP-1 and GIP receptor agonists (also referred to as “twincretins”). Tirzepatide simultaneously activates two incretin hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), both of which play crucial roles in regulating blood sugar and metabolism.